Fig. 6

Characterisation of the potential impact of efavirenz solid drug nanoparticles on monocyte derived macrophage function. MDM were treated with either efavirenz aqueous solution or efavirenz s for 24 h before their cytokine secretion (a) was assessed. LPS included as a positive control. Uptake of efavirenz s was also assessed (b) in addition to the phagocytic capacity of MDM treated with sample materials. Data expressed as mean ± standard deviation (N = 5); *P < 0.05, **P < 0.01, ***P<0.001 as compared to untreated control